Biovie Inc. (BIVI) · Nov 6, 2026 · Share issuance

BioVie financing raises $4.74M but adds 2.96M warrants

$4.74M financing — $4.74M gross proceeds; 2.96M shares plus 2.96M warrants

BioVie’s financing adds $4.74M of liquidity for its clinical programs, but the deal also brings immediate share issuance and substantial warrant dilution.

BioVie is a cash-burning, clinical-stage biotech trying to turn small Phase 2 signals for bezisterim into a Phase 3 Parkinson’s program, while also advancing Long COVID and BIV201 in liver disease.

The raise modestly extends BioVie’s ability to keep developing its pipeline. The company agreed to sell securities to a single healthcare-focused institutional investor, with proceeds earmarked for working capital and general corporate purposes.

Offering termsAmount
Common shares / equivalents (Offering)2,962,500
Purchase price (Offering)$1.60
Common warrants2,962,500
Warrant exercise price$1.70
Gross proceeds (Offering)$4.74M

The liquidity improvement is real but not transformative. BioVie had approximately $9.0 million of cash at June 30, 2026 and used approximately $19.0 million in operating cash during fiscal 2026, so this raise represents roughly one-quarter of its latest annual operating cash use. It helps fund the next stage of development, but does not remove the company’s dependence on further financing.

The cost is substantial potential dilution. The deal adds 2.96 million shares or equivalents immediately, plus warrants for another 2.96 million shares exercisable at $1.70. That is a standard financing structure for a small biotech, but it limits how much of the new cash represents clean progress for existing shareholders.

This funds the existing story rather than changing it. BioVie’s Phase 2 Parkinson’s findings and planned FDA discussions on a Phase 3 design were already public before this filing; the new information is the size and terms of the capital raise. 〔0〕

Bottom line: The financing reduces near-term funding pressure, but it is a bridge rather than a breakthrough. It modestly advances BioVie’s development plans while adding meaningful dilution and leaving additional capital needs in view.

What to watch next

FDA Phase 3 feedback expected before year-end

Original filing on SEC EDGAR

BioVie financing raises $4.74M but adds 2.96M warrants | BIVI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.